Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases

Journal of Neurochemistry

Volumn 114, Issue 5, 2010, Pages 1261-1276

  Kosloski, Lisa M ^a   Ha, Duy M ^a   Hutter, Jessica A L ^a   Stone, David K ^a   Pichler, Michael R ^a   Reynolds, Ashley D ^a   Gendelman, Howard E ^a   Mosley, R Lee ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

immunization; inflammation; microglia; neuroprotection; Parkinson's disease; regulatory T cells; therapeutic vaccination

Indexed keywords

ACETYLSALICYLIC ACID; IBUPROFEN; INDOMETACIN; MINOCYCLINE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTAGLANDIN SYNTHASE INHIBITOR;

ADAPTIVE IMMUNITY; ALZHEIMER DISEASE; CLINICAL TRIAL; DISEASE COURSE; DRUG MEGADOSE; ENCEPHALITIS; GERIATRIC CARE; GLIA CELL; HOMEOSTASIS; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOREGULATION; IMMUNOTHERAPY; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT;

ADAPTIVE IMMUNITY; ANIMALS; HOMEOSTASIS; HUMANS; NEURODEGENERATIVE DISEASES; NEUROGLIA;

EID: 77955160278     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2010.06834.x     Document Type: Review

References (178)

1. Adams D. O. Hamilton T. A. (1987) Molecular transductional mechanisms by which IFN gamma and other signals regulate macrophage development. Immunol. Rev. 97, 5 27.
2. Aggarwal S., Xie M. H., Maruoka M., Foster J. Gurney A. L. (2001) Acinar cells of the pancreas are a target of interleukin-22. J. Interferon Cytokine Res. 21, 1047 1053.
3. Ajmone-Cat M. A., Nicolini A. Minghetti L. (2003) Prolonged exposure of microglia to lipopolysaccharide modifies the intracellular signaling pathways and selectively promotes prostaglandin E2 synthesis. J. Neurochem. 87, 1193 1203.
4. Alafuzoff I., Overmyer M., Helisalmi S. Soininen H. (2000) Lower counts of astroglia and activated microglia in patients with Alzheimer's disease with regular use of non-steroidal anti-inflammatory drugs. J. Alzheimers Dis. 2, 37 46.
5. Aloisi F. (2001) Immune function of microglia. Glia 36, 165 179.
6. Anholt R. R., De Souza E. B., Oster-Granite M. L. Snyder S. H. (1985) Peripheral-type benzodiazepine receptors: autoradiographic localization in whole-body sections of neonatal rats. J. Pharmacol. Exp. Ther. 233, 517 526.
7. Atassi M. Z. Casali P. (2008) Molecular mechanisms of autoimmunity. Autoimmunity 41, 123 132.
8. Aubin N., Curet O., Deffois A. Carter C. (1998) Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J. Neurochem. 71, 1635 1642.
9. Babcock A. A., Kuziel W. A., Rivest S. Owens T. (2003) Chemokine expression by glial cells directs leukocytes to sites of axonal injury in the CNS. J. Neurosci. 23, 7922 7930.
10. Batchelor P. E., Liberatore G. T., Wong J. Y., Porritt M. J., Frerichs F., Donnan G. A. Howells D. W. (1999) Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. J. Neurosci. 19, 1708 1716.
11. Batchelor P. E., Liberatore G. T., Porritt M. J., Donnan G. A. Howells D. W. (2000) Inhibition of brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor expression reduces dopaminergic sprouting in the injured striatum. Eur. J. Neurosci. 12, 3462 3468.
12. Bazan N. G., Colangelo V. Lukiw W. J. (2002) Prostaglandins and other lipid mediators in Alzheimer's disease. Prostaglandins Other Lipid Mediat. 68-69, 197 210.
13. Benner E. J., Mosley R. L., Destache C. J. et al. (2004) Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc. Natl Acad. Sci. USA 101, 9435 9440.
14. Benner E. J., Banerjee R., Reynolds A. D. et al. (2008) Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS ONE 3, e1376.
15. Black K. L., Ikezaki K., Santori E., Becker D. P. Vinters H. V. (1990) Specific high-affinity binding of peripheral benzodiazepine receptor ligands to brain tumors in rat and man. Cancer 65, 93 97.
16. Blasko I. Grubeck-Loebenstein B. (2003) Role of the immune system in the pathogenesis, prevention and treatment of Alzheimer's disease. Drugs Aging 20, 101 113.
17. von Bohlen Und Halbach O. (2005) Modeling neurodegenerative diseases in vivo review. Neurodegener. Dis. 2, 313 320.
18. Breitner J. C., Haneuse S. J., Walker R., Dublin S., Crane P. K., Gray S. L. Larson E. B. (2009) Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology 72, 1899 1905.
19. Brooks D. J., Frey K. A., Marek K. L., Oakes D., Paty D., Prentice R., Shults C. W. Stoessl A. J. (2003) Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp. Neurol. 184, S68 S79.
20. Burke R. E., Antonelli M. Sulzer D. (1998) Glial cell line-derived neurotrophic growth factor inhibits apoptotic death of postnatal substantia nigra dopamine neurons in primary culture. J. Neurochem. 71, 517 525.
21. +: differential requirement for neuronal cyclooxygenase activity. J. Neurosci. Res. 81, 121 131.
22. Casper D., Yaparpalvi U., Rempel N. Werner P. (2000) Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro. Neurosci. Lett. 289, 201 204.
23. Chapoval S., Dasgupta P., Dorsey N. J. Keegan A. D. (2010) Regulation of the T helper cell type 2 (Th2)/T regulatory cell (Treg) balance by IL-4 and STAT6. J. Leukoc. Biol. 87, 1011 1018.
24. Chatenoud L. (2010) Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies? Nat. Rev. Endocrinol. 6, 149 157.
25. Chatenoud L. Bluestone J. A. (2007) CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat. Rev. Immunol. 7, 622 632.
26. Chen M., Ona V. O., Li M. et al. (2000) Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med. 6, 797 801.
27. Chen H., Zhang S. M., Hernan M. A., Schwarzschild M. A., Willett W. C., Colditz G. A., Speizer F. E. Ascherio A. (2003) Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch. Neurol. 60, 1059 1064.
28. Chen H., Jacobs E., Schwarzschild M. A., McCullough M. L., Calle E. E., Thun M. J. Ascherio A. (2005) Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann. Neurol. 58, 963 967. (Pubitemid 41746889)
29. Combs C. K., Johnson D. E., Karlo J. C., Cannady S. B. Landreth G. E. (2000) Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J. Neurosci. 20, 558 567.
30. Cuello A. C., Ferretti M. T., Leon W. C., Iulita M. F., Melis T., Ducatenzeiler A., Bruno M. A. Canneva F. (2010) Early-stage inflammation and experimental therapy in transgenic models of the Alzheimer-like amyloid pathology. Neurodegener. Dis. 7, 96 98.
31. Dauer W. Przedborski S. (2003) Parkinson's disease: mechanisms and models. Neuron 39, 889 909.
32. De Souza E. B., Anholt R. R., Murphy K. M., Snyder S. H. Kuhar M. J. (1985) Peripheral-type benzodiazepine receptors in endocrine organs: autoradiographic localization in rat pituitary, adrenal, and testis. Endocrinology 116, 567 573.
33. Delgado M., Chorny A., Gonzalez-Rey E. Ganea D. (2005) Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo. J. Leukoc. Biol. 78, 1327 1338.
34. +-induced degeneration: an in vivo microdialysis study. Ann. N Y Acad. Sci. 1089, 462 471. (Pubitemid 47092070)
35. Di Matteo V., Pierucci M., Di Giovanni G., Di Santo A., Poggi A., Benigno A. Esposito E. (2006b) Aspirin protects striatal dopaminergic neurons from neurotoxin-induced degeneration: an in vivo microdialysis study. Brain Res. 1095, 167 177. (Pubitemid 43884742)
36. Diguet E., Fernagut P. O., Wei X., Du Y., Rouland R., Gross C., Bezard E. Tison F. (2004) Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease. Eur. J. Neurosci. 19, 3266 3276.
37. Du Y., Ma Z., Lin S. et al. (2001) Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl Acad. Sci. USA 98, 14669 14674.
38. Eberhardt O., Coelln R. V., Kugler S. et al. (2000) Protection by synergistic effects of adenovirus-mediated X-chromosome-linked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J. Neurosci. 20, 9126 9134.
39. Edwards J. P., Zhang X., Frauwirth K. A. Mosser D. M. (2006) Biochemical and functional characterization of three activated macrophage populations. J. Leukoc. Biol. 80, 1298 1307.
40. Etminan M., Gill S. Samii A. (2003) Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ 327, 128.
41. Feng Z., Li D., Fung P. C., Pei Z., Ramsden D. B. Ho S. L. (2003) COX-2-deficient mice are less prone to MPTP-neurotoxicity than wild-type mice. Neuroreport 14, 1927 1929.
42. Ferger B., Teismann P., Earl C. D., Kuschinsky K. Oertel W. H. (1999) Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice. Naunyn Schmiedebergs Arch. Pharmacol. 360, 256 261.
43. Fox S. H. Lang A. E. (2008) Levodopa-related motor complications- phenomenology. Mov. Disord. 23, S509 S514.
44. Frankish H. (2002) Why do COX-2 inhibitors increase risk of cardiovascular events? Lancet 359, 1410.
45. Gagne J. J. Power M. C. (2010) Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology 74, 995 1002.
46. Gambineri E., Perroni L., Passerini L. et al. (2008) Clinical and molecular profile of a new series of patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: inconsistent correlation between forkhead box protein 3 expression and disease severity. J. Allergy Clin. Immunol. 122, 1105 1112.
47. Gangi E., Vasu C., Cheatem D. Prabhakar B. S. (2005) IL-10-producing CD4+CD25+ regulatory T cells play a critical role in granulocyte-macrophage colony-stimulating factor-induced suppression of experimental autoimmune thyroiditis. J. Immunol. 174, 7006 7013.
48. Gao H. M., Hong J. S., Zhang W. Liu B. (2003) Synergistic dopaminergic neurotoxicity of the pesticide rotenone and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. J. Neurosci. 23, 1228 1236.
49. Gao X., Chen H., Schwarzschild M. Ascherio A. (2010) Use of Non-Steroidal Anti-Inflammatory Drugs and Risk of Parkinson's Disease: A Prospective Study and Meta-Analysis. Oral presentation S03.003, 62nd American Academy of Neurology, Toronto, Canada, April 13.
50. Gash D. M., Zhang Z., Ovadia A. et al. (1996) Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380, 252 255.
51. Gebicke-Haerter P. J. (2001) Microglia in neurodegeneration: molecular aspects. Microsc. Res. Tech. 54, 47 58.
52. Gerhard A., Pavese N., Hotton G. et al. (2006) In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol. Dis. 21, 404 412. (Pubitemid 43099863)
53. Gilman S., Koller M., Black R. S. et al. (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64, 1553 1562.
54. Gonzalez-Rey E., Chorny A., Fernandez-Martin A., Ganea D. Delgado M. (2006) Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells. Blood 107, 3632 3638.
55. Gordon P. H., Moore D. H., Miller R. G. et al. (2007) Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 6, 1045 1053.
56. Gratchev A., Kzhyshkowska J., Utikal J. Goerdt S. (2005) Interleukin-4 and dexamethasone counterregulate extracellular matrix remodelling and phagocytosis in type-2 macrophages. Scand. J. Immunol. 61, 10 17.
57. Gregori S., Giarratana N., Smiroldo S., Uskokovic M. Adorini L. (2002) A 1alpha,25-dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes 51, 1367 1374.
58. Griffin R., Nally R., Nolan Y., McCartney Y., Linden J. Lynch M. A. (2006) The age-related attenuation in long-term potentiation is associated with microglial activation. J. Neurochem. 99, 1263 1272.
59. Hecker A., Kaufmann A., Hecker M., Padberg W. Grau V. (2009) Expression of interleukin-21, interleukin-21 receptor alpha and related type I cytokines by intravascular graft leukocytes during acute renal allograft rejection. Immunobiology 214, 41 49.
60. Herold K. C., Gitelman S., Greenbaum C. et al. (2009) Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin. Immunol. 132, 166 173.
61. Hoozemans J. J., Rozemuller A. J., Janssen I., De Groot C. J., Veerhuis R. Eikelenboom P. (2001) Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain. Acta Neuropathol. 101, 2 8.
62. Hsu H. C., Yang P., Wang J. et al. (2008) Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat. Immunol. 9, 166 175.
63. Huber S., Stahl F. R., Schrader J. et al. (2009) Activin a promotes the TGF-beta-induced conversion of CD4+CD25- T cells into Foxp3+ induced regulatory T cells. J. Immunol. 182, 4633 4640.
64. Huppa J. B. Davis M. M. (2003) T-cell-antigen recognition and the immunological synapse. Nat. Rev. Immunol. 3, 973 983.
65. Imamura K., Hishikawa N., Ono K., Suzuki H., Sawada M., Nagatsu T., Yoshida M. Hashizume Y. (2005) Cytokine production of activated microglia and decrease in neurotrophic factors of neurons in the hippocampus of Lewy body disease brains. Acta Neuropathol. 109, 141 150.
66. Iwakura Y., Nakae S., Saijo S. Ishigame H. (2008) The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol. Rev. 226, 57 79.
67. Janus C., Pearson J., McLaurin J. et al. (2000) A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979 982.
68. Junck L., Olson J. M., Ciliax B. J. et al. (1989) PET imaging of human gliomas with ligands for the peripheral benzodiazepine binding site. Ann. Neurol. 26, 752 758.
69. Kakimura J., Kitamura Y., Takata K., Kohno Y., Nomura Y. Taniguchi T. (2001) Release and aggregation of cytochrome c and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole. Eur. J. Pharmacol. 417, 59 67.
70. Kim H. S. Suh Y. H. (2009) Minocycline and neurodegenerative diseases. Behav. Brain Res. 196, 168 179.
71. Klegeris A. McGeer P. L. (2005) Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease. Curr. Alzheimer Res. 2, 355 365.
72. Koenen H. J., Smeets R. L., Vink P. M., van Rijssen E., Boots A. M. Joosten I. (2008) Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 112, 2340 2352.
73. Kohm A. P., Williams J. S., Bickford A. L., McMahon J. S., Chatenoud L., Bach J. F., Bluestone J. A. Miller S. D. (2005) Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J. Immunol. 174, 4525 4534.
74. Kokjohn T. A. Roher A. E. (2009) Antibody responses, amyloid-beta peptide remnants and clinical effects of AN-1792 immunization in patients with AD in an interrupted trial. CNS Neurol. Disord. Drug Targets 8, 88 97.
75. Kordower J. H., Emborg M. E., Bloch J. et al. (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290, 767 773.
76. Korecka J. A., Verhaagen J. Hol E. M. (2007) Cell-replacement and gene-therapy strategies for Parkinson's and Alzheimer's disease. Regen. Med. 2, 425 446.
77. Korn T., Bettelli E., Oukka M. Kuchroo V. K. (2009) IL-17 and Th17 Cells. Annu. Rev. Immunol. 27, 485 517.
78. Kriz J., Nguyen M. D. Julien J. P. (2002) Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 10, 268 278.
79. Lang A. E., Gill S., Patel N. K. et al. (2006) Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 59, 459 466.
80. Laurie C., Reynolds A., Coskun O., Bowman E., Gendelman H. E. Mosley R. L. (2007) CD4+ T cells from Copolymer-1 immunized mice protect dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J. Neuroimmunol. 183, 60 68.
81. Leceta J., Gomariz R. P., Martinez C., Carrion M., Arranz A. Juarranz Y. (2007) Vasoactive intestinal peptide regulates Th17 function in autoimmune inflammation. Neuroimmunomodulation 14, 134 138.
82. Lee H. J., Patel S. Lee S. J. (2005) Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J. Neurosci. 25, 6016 6024.
83. Leidi M., Gotti E., Bologna L. et al. (2009) M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. J. Immunol. 182, 4415 4422.
84. Lemere C. A., Maron R., Spooner E. T., Grenfell T. J., Mori C., Desai R., Hancock W. W., Weiner H. L. Selkoe D. J. (2000) Nasal A beta treatment induces anti-A beta antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann. N Y Acad. Sci. 920, 328 331.
85. Lleo A., Galea E. Sastre M. (2007) Molecular targets of non-steroidal anti-inflammatory drugs in neurodegenerative diseases. Cell. Mol. Life Sci. 64, 1403 1418.
86. Luchtman D. W., Shao D. Song C. (2009) Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease. Physiol. Behav. 98, 130 138.
87. +-induced mitochondrial damage and superoxide anion generation. Life Sci. 78, 2438 2443.
88. Marek K., Innis R., van Dyck C., Fussell B., Early M., Eberly S., Oakes D. Seibyl J. (2001) [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 57, 2089 2094.
89. Martin W. R., Wieler M., Gee M., Hanstock C. C. Camicioli R. M. (2008) Intact presupplementary motor area function in early, untreated Parkinson's disease. Mov. Disord. 23, 1756 1759.
90. Masliah E., Rockenstein E., Adame A. et al. (2005) Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46, 857 868.
91. McGeer P. L. McGeer E. G. (2007) NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol. Aging 28, 639 647.
92. McGeer E. G., Singh E. A. McGeer P. L. (1988) Peripheral-type benzodiazepine binding in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2, 331 336.
93. Meinert C. L., McCaffrey L. D. Breitner J. C. (2009) Alzheimer's Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results. Alzheimers Dement. 5, 93 104.
94. de Meira Santos Lima M., Braga Reksidler A., Marques Zanata S., Bueno Machado H., Tufik S. Vital M. A. (2006) Different parkinsonism models produce a time-dependent induction of COX-2 in the substantia nigra of rats. Brain Res. 1101, 117 125.
95. Meredith G. E., Totterdell S., Potashkin J. A. Surmeier D. J. (2008) Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol. Parkinsonism Relat. Disord. 14, S112 S115.
96. Minati L., Edginton T., Bruzzone M. G. Giaccone G. (2009) Current concepts in Alzheimer's disease: a multidisciplinary review. Am. J. Alzheimers Dis. Other Demen. 24, 95 121.
97. Mohanakumar K. P., Muralikrishnan D. Thomas B. (2000) Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced neurotoxicity. Brain Res. 864, 281 290.
98. Monteleone G., Pallone F. Macdonald T. T. (2009) Interleukin-21 as a new therapeutic target for immune-mediated diseases. Trends Pharmacol. Sci. 30, 441 447.
99. Morgan D., Diamond D. M., Gottschall P. E. et al. (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982 985.
100. + in PC12 cells. J. Pharmacol. Exp. Ther. 310, 800 807.
101. Mosley R. L., Benner E. J., Kadiu I., Thomas M., Boska M. D., Hasan K., Laurie C. Gendelman H. E. (2006) Neuroinflammation, oxidative stress and the pathogenesis of Parkinson's disease. Clin. Neurosci. Res. 6, 261 281.
102. Mosser D. M. (2003) The many faces of macrophage activation. J. Leukoc. Biol. 73, 209 212.
103. Mozley P. D., Schneider J. S., Acton P. D. et al. (2000) Binding of [99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers. J. Nucl. Med. 41, 584 589.
104. Nakae S., Saijo S., Horai R., Sudo K., Mori S. Iwakura Y. (2003) IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc. Natl Acad. Sci. USA 100, 5986 5990.
105. Netland E. E., Newton J. L., Majocha R. E. Tate B. A. (1998) Indomethacin reverses the microglial response to amyloid beta-protein. Neurobiol. Aging 19, 201 204.
106. NINDS NET-PD Investigators (2006) A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66, 664 671.
107. NINDS NET-PD Investigators (2008) A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin. Neuropharmacol. 31, 141 150.
108. Noble W., Garwood C., Stephenson J., Kinsey A. M., Hanger D. P. Anderton B. H. (2009) Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease. FASEB J. 23, 739 750.
109. Notley C. A., McCann F. E., Inglis J. J. Williams R. O. (2010) ANTI-CD3 therapy expands the numbers of CD4+ and CD8+ Treg cells and induces sustained amelioration of collagen-induced arthritis. Arthritis Rheum. 62, 171 178.
110. Nutt J. G., Burchiel K. J., Comella C. L. et al. (2003) Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60, 69 73.
111. Olanow C. W., Stern M. B. Sethi K. (2009) The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 72, S1 S136.
112. Onishi Y., Fehervari Z., Yamaguchi T. Sakaguchi S. (2008) Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc. Natl Acad. Sci. USA 105, 10113 10118.
113. Owen F., Poulter M., Waddington J. L., Mashal R. D. Crow T. J. (1983) [3H]R05-4864 and [3H]flunitrazepam binding in kainate-lesioned rat striatum and in temporal cortex of brains from patients with senile dementia of the Alzheimer type. Brain Res. 278, 373 375.
114. Ozdemir C., Akdis M. Akdis C. A. (2009) T regulatory cells and their counterparts: masters of immune regulation. Clin. Exp. Allergy 39, 626 639.
115. Pasqualetti P., Bonomini C., Dal Forno G., Paulon L., Sinforiani E., Marra C., Zanetti O. Rossini P. M. (2009) A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease. Aging Clin. Exp. Res. 21, 102 110.
116. Pate B. D., Kawamata T., Yamada T., McGeer E. G., Hewitt K. A., Snow B. J., Ruth T. J. Calne D. B. (1993) Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann. Neurol. 34, 331 338.
117. Patel N. K., Bunnage M., Plaha P., Svendsen C. N., Heywood P. Gill S. S. (2005) Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann. Neurol. 57, 298 302.
118. Perry V. H., Newman T. A. Cunningham C. (2003) The impact of systemic infection on the progression of neurodegenerative disease. Nat. Rev. Neurosci. 4, 103 112.
119. Pride M., Seubert P., Grundman M., Hagen M., Eldridge J. Black R. S. (2008) Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis. Neurodegener. Dis. 5, 194 196.
120. Quintero E. M., Willis L., Singleton R., Harris N., Huang P., Bhat N. Granholm A. C. (2006) Behavioral and morphological effects of minocycline in the 6-hydroxydopamine rat model of Parkinson's disease. Brain Res. 1093, 198 207.
121. Ramaker C., Marinus J., Stiggelbout A. M. Van Hilten B. J. (2002) Systematic evaluation of rating scales for impairment and disability in Parkinson's disease. Mov. Disord. 17, 867 876.
122. Ramsay S. C., Weiller C., Myers R., Cremer J. E., Luthra S. K., Lammertsma A. A. Frackowiak R. S. (1992) Monitoring by PET of macrophage accumulation in brain after ischaemic stroke. Lancet 339, 1054 1055.
123. Ravina B., Eidelberg D., Ahlskog J. E. et al. (2005) The role of radiotracer imaging in Parkinson disease. Neurology 64, 208 215.
124. Reines S. A., Block G. A., Morris J. C., Liu G., Nessly M. L., Lines C. R., Norman B. A. Baranak C. C. (2004) Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 62, 66 71.
125. Reynolds A. D., Banerjee R., Liu J., Gendelman H. E. Mosley R. L. (2007) Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease. J. Leukoc. Biol. 82, 1083 1094.
126. Reynolds A. D., Glanzer J. G., Kadiu I. et al. (2008a) Nitrated alpha-synuclein-activated microglial profiling for Parkinson's disease. J. Neurochem. 104, 1504 1525.
127. Reynolds A. D., Kadiu I., Garg S. K., Glanzer J. G., Nordgren T., Ciborowski P., Banerjee R. Gendelman H. E. (2008b) Nitrated alpha-synuclein and microglial neuroregulatory activities. J. Neuroimmune Pharmacol. 3, 59 74.
128. Reynolds A. D., Stone D. K., Mosley R. L. Gendelman H. E. (2009a) Nitrated [alpha]-synuclein-induced alterations in microglial immunity are regulated by CD4+ T cell subsets. J. Immunol. 182, 4137 4149.
129. Reynolds A. D., Stone D. K., Mosley R. L. Gendelman H. E. (2009b) Proteomic studies of nitrated alpha-synuclein microglia regulation by CD4+CD25+ T cells. J. Proteome Res. 8, 3495 3511.
130. Reynolds A. D., Stone D. K., Hutter J. A., Benner E. J., Mosley R. L. Gendelman H. E. (2010) Regulatory T cells attenuate th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease. J. Immunol. 184, 2261 2271.
131. Rich J. B., Rasmusson D. X., Folstein M. F., Carson K. A., Kawas C. Brandt J. (1995) Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 45, 51 55.
132. Sakaguchi S. (2004) Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22, 531 562.
133. Sakaguchi S., Sakaguchi N., Asano M., Itoh M. Toda M. (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155, 1151 1164.
134. Savitt J. M., Dawson V. L. Dawson T. M. (2006) Diagnosis and treatment of Parkinson disease: molecules to medicine. J. Clin. Invest. 116, 1744 1754.
135. Schenk D., Barbour R., Dunn W. et al. (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173 177.
136. Schoemaker H., Morelli M., Deshmukh P. Yamamura H. I. (1982) [3H]Ro5-4864 benzodiazepine binding in the kainate lesioned striatum and Huntington's diseased basal ganglia. Brain Res. 248, 396 401.
137. Seabrook T. J., Jiang L., Maier M. Lemere C. A. (2006) Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice. Glia 53, 776 782.
138. Seibyl J. P., Marek K., Sheff K., Zoghbi S., Baldwin R. M., Charney D. S., van Dyck C. H. Innis R. B. (1998) Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. J. Nucl. Med. 39, 1500 1508.
139. Senior K. (2002) Dosing in phase II trial of Alzheimer's vaccine suspended. Lancet Neurol. 1, 3.
140. Shie F. S. Woltjer R. L. (2007) Manipulation of microglial activation as a therapeutic strategy in Alzheimer's disease. Curr. Med. Chem. 14, 2865 2871.
141. Shriver L. P., Koudelka K. J. Manchester M. (2009) Viral nanoparticles associate with regions of inflammation and blood brain barrier disruption during CNS infection. J. Neuroimmunol. 211, 66 72.
142. Singh R., Kumar R. Singh D. P. (2009) Nitric oxide-releasing nonsteroidal anti-inflammatory drugs: gastrointestinal-sparing potential drugs. J. Med. Food 12, 208 218.
143. Slevin J. T., Gash D. M., Smith C. D., Gerhardt G. A., Kryscio R., Chebrolu H., Walton A., Wagner R. Young A. B. (2007) Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal. J. Neurosurg. 106, 614 620.
144. Snow B. J., Vingerhoets F. J., Langston J. W., Tetrud J. W., Sossi V. Calne D. B. (2000) Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism. J. Neurol. Neurosurg. Psychiatry 68, 313 316.
145. Sriram K., Miller D. B. O'Callaghan J. P. (2006) Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha. J. Neurochem. 96, 706 718.
146. Stephenson D. T., Schober D. A., Smalstig E. B., Mincy R. E., Gehlert D. R. Clemens J. A. (1995) Peripheral benzodiazepine receptors are colocalized with activated microglia following transient global forebrain ischemia in the rat. J. Neurosci. 15, 5263 5274.
147. Stewart W. F., Kawas C., Corrada M. Metter E. J. (1997) Risk of Alzheimer's disease and duration of NSAID use. Neurology 48, 626 632.
148. Stone D. K., Reynolds A. D., Mosley R. L. Gendelman H. E. (2009) Innate and adaptive immunity for the pathobiology of Parkinson's disease. Antioxid. Redox Signal. 11, 2151 2166.
149. Stratman N. C., Carter D. B. Sethy V. H. (1997) Ibuprofen: effect on inducible nitric oxide synthase. Brain Res. Mol. Brain Res. 50, 107 112.
150. Sung J. Y., Park S. M., Lee C. H. et al. (2005) Proteolytic cleavage of extracellular secreted [alpha]-synuclein via matrix metalloproteinases. J. Biol. Chem. 280, 25216 25224.
151. Suzuki Y., Claflin J., Wang X., Lengi A. Kikuchi T. (2005) Microglia and macrophages as innate producers of interferon-gamma in the brain following infection with Toxoplasma gondii. Int. J. Parasitol. 35, 83 90.
152. Szekely C. A., Thorne J. E., Zandi P. P., Ek M., Messias E., Breitner J. C. Goodman S. N. (2004) Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 23, 159 169.
153. Taher Y. A., van Esch B. C., Hofman G. A., Henricks P. A. van Oosterhout A. J. (2008) 1alpha,25-dihydroxyvitamin D3 potentiates the beneficial effects of allergen immunotherapy in a mouse model of allergic asthma: role for IL-10 and TGF-beta. J. Immunol. 180, 5211 5221.
154. Tao R., de Zoeten E. F., Ozkaynak E. et al. (2007) Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat. Med. 13, 1299 1307.
155. Teismann P. Ferger B. (2001) Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 39, 167 174.
156. Teismann P., Tieu K., Choi D. K., Wu D. C., Naini A., Hunot S., Vila M., Jackson-Lewis V. Przedborski S. (2003) Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc. Natl Acad. Sci. USA 100, 5473 5478.
157. Tikka T. M. Koistinaho J. E. (2001) Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. J. Immunol. 166, 7527 7533.
158. Tikka T., Fiebich B. L., Goldsteins G., Keinanen R. Koistinaho J. (2001) Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J. Neurosci. 21, 2580 2588.
159. Tomas-Camardiel M., Rite I., Herrera A. J., de Pablos R. M., Cano J., Machado A. Venero J. L. (2004) Minocycline reduces the lipopolysaccharide- induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood-brain barrier, and damage in the nigral dopaminergic system. Neurobiol. Dis. 16, 190 201.
160. Tyurina Y. Y., Kapralov A. A., Jiang J. et al. (2006) Oxidation and cytotoxicity of 6-OHDA are mediated by reactive intermediates of COX-2 overexpressed in PC12 cells. Brain Res. 1093, 71 82.
161. Van Camp N., Boisgard R., Kuhnast B. et al. (2010) In vivo imaging of neuroinflammation: a comparative study between [(18)F]PBR111, [(11)C]CLINME and [(11)C]PK11195 in an acute rodent model. Eur. J. Nucl. Med. Mol. Imaging 37, 962 972.
162. Van Gool W. A., Weinstein H. C., Scheltens P. Walstra G. J. (2001) Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet 358, 455 460.
163. Vasu C., Dogan R. N., Holterman M. J. Prabhakar B. S. (2003) Selective induction of dendritic cells using granulocyte macrophage-colony stimulating factor, but not fms-like tyrosine kinase receptor 3-ligand, activates thyroglobulin-specific CD4+/CD25+ T cells and suppresses experimental autoimmune
164. t' Veld B. A., Ruitenberg A., Hofman A., Launer L. J., van Duijn C. M., Stijnen T., Breteler M. M. Stricker B. H. (2001) Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N. Engl. J. Med. 345, 1515 1521.
165. Vellas B., Black R., Thal L. J. et al. (2009) Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr. Alzheimer Res. 6, 144 151.
166. Vijitruth R., Liu M., Choi D. Y., Nguyen X. V., Hunter R. L. Bing G. (2006) Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease. J. Neuroinflammation 3, 6.
167. +-induced COX-2 activation and subsequent dopaminergic neurodegeneration. FASEB J. 19, 1134 1136.
168. Weiner H. L. (2008) A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis. J. Neurol. 255, 3 11.
169. Weiner H. L. (2009) The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann. Neurol. 65, 239 248.
170. Weiner H. L., Lemere C. A., Maron R., Spooner E. T., Grenfell T. J., Mori C., Issazadeh S., Hancock W. W. Selkoe D. J. (2000) Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann. Neurol. 48, 567 579.
171. Wu D. C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D. K., Ischiropoulos H. Przedborski S. (2002) Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22, 1763 1771.
172. Xinqiang S., Fei L., Nan L. et al. (2010) Therapeutic efficacy of experimental rheumatoid arthritis with low-dose methotrexate by increasing partially CD4(+)CD25(+)Treg cells and inducing Th1 to Th2 shift in both cells and cytokines. Biomed. Pharmacother. [Epub ahead of print].
173. Yamamoto K., Arakawa T., Ueda N. Yamamoto S. (1995) Transcriptional roles of nuclear factor kappa B and nuclear factor-interleukin-6 in the tumor necrosis factor alpha-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. J. Biol. Chem. 270, 31315 31320.
174. Yang L., Sugama S., Chirichigno J. W. et al. (2003) Minocycline enhances MPTP toxicity to dopaminergic neurons. J. Neurosci. Res. 74, 278 285.
175. Yasojima K., Schwab C., McGeer E. G. McGeer P. L. (1999) Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Brain Res. 830, 226 236.
176. Yasuno F., Ota M., Kosaka J. et al. (2008) Increased binding of peripheral benzodiazepine receptor in Alzheimer's disease measured by positron emission tomography with [11C]DAA1106. Biol. Psychiatry 64, 835 841.
177. Zandi P. P., Anthony J. C., Hayden K. M., Mehta K., Mayer L. Breitner J. C. (2002) Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology 59, 880 886.
178. Zhu S., Stavrovskaya I. G., Drozda M. et al. (2002) Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417, 74 78.